Can Özlü: Can the HALP Score Help Identify Thrombotic Risk in Myeloproliferative Neoplasms?
Can Özlü, General Manager at CAS Industrial Health Products Trading Ltd. Co., Associate Professor at Kütahya Health Sciences University, Special Education Specialist at KSBÜ Society for Computational Sciences and Innovative Technology in Healthcare, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Medical Records, adding:
“Can routine laboratory data help us recognize thrombotic risk in myeloproliferative neoplasms more clearly?
Our new study, now available in the official Medical Records archive, evaluated the HALP score and systemic immune-inflammation index (SII) in 93 patients with polycythemia vera or essential thrombocythemia.
Thrombosis occurred in 27 patients. HALP scores were lower in patients with thrombosis, and HALP showed moderate discrimination in ROC analysis (AUC 0.723). At a cutoff of 32.2, sensitivity was 70.6% and specificity 59.4%. SII, by contrast, did not reach statistical significance.
The clinically important message is one of possibility, not proof. This was a retrospective, single-center study with a limited sample, so HALP should not replace established risk models or guide treatment on its own. It is a practical, inexpensive candidate marker that deserves prospective and external validation.
I thank my co-authors Cumali Yalçın, Aycan Acet, Aysun Gönderen and Ezgi Feyza Aydın for this collaboration.
What validation would you consider essential before a composite laboratory score could influence clinical decisions?”
Title: Utilization of HALP and Systemic Immune-Inflammation Index for Thrombotic Risk in Polycythemia Vera and Essential Thrombocythemia
Authors: Cumali Yalcin, Aycan Acet, Aysun Gonderen, Ezgi Feyza Aydin, Can Ozlu
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 9, 2026, 14:54Agnes Kisakye: Expanding Point-of-Care Ultrasound and Surgical Interventions for Hemophilia in Uganda
-
Sep 9, 2026, 14:52Jan Sloves: Addressing Diagnostic and Treatment Variability in Pelvic-Origin Varicose Veins
-
Sep 9, 2026, 14:48The French Care Pathway for Gene Therapy in Haemophilia B – CRH French Reference Center for Hemophilia Lyon
-
Sep 9, 2026, 14:43David McIntosh: The Ethics of Plasma Donation
-
Sep 9, 2026, 14:42Thirunavukkarasu Angappan: Factor VIII and IX Didn’t Get Viral-Safety Rules Until the 1980s
-
Sep 9, 2026, 14:30Alejandro González Veliz: 2026 ESC Guidelines Expand Cardiac Rehabilitation Beyond Post-Event Recovery
-
Sep 9, 2026, 13:59Natalie Arnold: Biomarkers and the Hidden Burden of CHD
-
Sep 9, 2026, 13:11Ron DePinho: A Negative Trial Does Not Repudiate Inflammation as a Cardiovascular Target
-
Sep 9, 2026, 13:10Ahmad Gharehbaghian: Visiting the Alborz Provincial Blood Transfusion Center